Register Login

Tenax Therapeutics Inc. (TENX)

Director Giordano Christopher Thomas 🟢 acquired 2.2M shares (6 derivative) of TENAX THERAPEUTICS, INC. (TENX) at $3,152.00 ($22.3M) Transaction Date: Jan 09, 2026 | Filing ID: 000001

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 2:26 p.m.

    🔍 Giordano Christopher Thomas (Director)

    Company: TENAX THERAPEUTICS, INC. (TENX)

    Report Date: 2026-01-09

    Transaction Summary:

    • Total transactions: 7
    • Derivative instruments: 6
    • Holdings reported: 6
    • Total shares acquired: 450,000
    • Total shares held: 2,653,324

    Detailed Transactions and Holdings:

    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-01-09 | Code: H | shares_owned_after: 2,605.00
    • Acquired 450,000 shares of Stock Option (right to buy) at $13.3 per share (Derivative)
      Date: 2026-01-09 | Code: A | Expires: 2036-01-09 | equity_swap_involved: 0 | shares_owned_after: 450,000.00 | transaction_form_type: 4 | Footnotes: F1
    • Holds 157 shares of Stock Option (right to buy) at $3152.0 per share (Derivative)
      Date: 2026-01-09 | Code: H | Expires: 2031-07-06 | shares_owned_after: 157.00 | Footnotes: F2
    • Holds 125 shares of Stock Option (right to buy) at $992.0 per share (Derivative)
      Date: 2026-01-09 | Code: H | Expires: 2032-06-09 | shares_owned_after: 125.00 | Footnotes: F3
    • Holds 437 shares of Stock Option (right to buy) at $3.549 per share (Derivative)
      Date: 2026-01-09 | Code: H | Expires: 2034-05-17 | shares_owned_after: 437.00 | Footnotes: F4
    • Holds 1,250,000 shares of Stock Option (right to buy) at $5.94 per share (Derivative)
      Date: 2026-01-09 | Code: H | Expires: 2034-12-10 | Exercise: 2025-12-10 | shares_owned_after: 1,250,000.00
    • Holds 1,400,000 shares of Stock Option (right to buy) at $5.89 per share (Derivative)
      Date: 2026-01-09 | Code: H | Expires: 2035-05-16 | shares_owned_after: 1,400,000.00 | Footnotes: F5

    Footnotes:

    • F1: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
    • F2: The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
    • F3: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
    • F4: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
    • F5: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

Search

News categories